Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AREXVY phase 3 efficacy and annual revaccination study in adults aged 60 years and older
jRCT2031210109Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing AREXVY with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Reported vaccine efficacy against RSV-associated LRTD. Started Jun 2021; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031210109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210109.